Lakewood-Amedex Biotherapeutics Inc LABT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.36 down $0.18, 33.43% on Nov 6
Last price · Previous close $0.54
- Market cap
- At the last price
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.36down $0.18, 33.43%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.54Nov 5
- Volume720.49MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume38.14MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.17 to $98.20; now $0.36
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LABT trailed the S&P 500 in both periods.
| Period | LABT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LABT: down 58.5% S&P 500: down 5.6% | LABT trailed the S&P 500 by 52.9 percentage points Trailed |
| 3M | LABT: down 83.9% S&P 500: down 4.1% | LABT trailed the S&P 500 by 79.8 percentage points Trailed |
LABT trailed the S&P 500 in both periods.
| Period | LABT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LABT: down 58.5% S&P 500: down 5.6% | LABT trailed the S&P 500 by 52.9 percentage points Trailed |
| 3M | LABT: down 83.9% S&P 500: down 4.3% | LABT trailed the S&P 500 by 79.6 percentage points Trailed |
All-time high
$86.50
Closing high on . Now 99.6% below that record.
Split-adjusted daily closes since Apr 23, 2026.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$7.35M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$1.94M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$854.54K | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$539.62K | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$655.94K | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$1.91M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$744.92K | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$923.29K | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$3.77M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY23 (Dec 31, 2023) | $0.00 | −$8.28M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$4.86M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$3.85M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- Not reportedLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flowNot reportedLast 12 months
- Capital spendingNot reportedLast 12 months
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $4.58MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$101.62KAs of Jun 30, 2026
- Net cash$4.48MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 7.70As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.02As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −443.7%Last 12 months
Over the last 12 months, Lakewood-Amedex Biotherapeutics’s net loss was 443.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Lakewood-Amedex Biotherapeutics Inc
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin ® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LABT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LABT stock FAQ
What is LABT stock’s price today?
Lakewood-Amedex Biotherapeutics (LABT) traded at $0.36 as of , down $0.18 (33.43%) from the previous close of $0.54. Over the past 52 weeks it has traded between $0.17 and $98.20.
Does LABT pay a dividend?
Lakewood-Amedex Biotherapeutics hasn’t paid a dividend in the last twelve months.
What is LABT’s 52-week high and low?
Over the past 52 weeks LABT has traded as low as $0.17 and as high as $98.20. At $0.36 as of , it is 99.6% below that high and 113.3% above the low.
What is LABT’s all-time high?
LABT’s highest closing price was $86.50 on , adjusted for stock splits. At $0.36 as of , it is 99.6% below that record.
Has LABT stock ever split?
Yes, once: 1-for-10 on .
What sector and industry is Lakewood-Amedex Biotherapeutics in?
Lakewood-Amedex Biotherapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Florida, USA.
What exchange does LABT trade on?
Lakewood-Amedex Biotherapeutics trades on the Nasdaq under the ticker symbol LABT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.